Advanced Flavivirus Vaccine Platform

A next-generation vaccine platform utilizing recombinant measles virus vectors to induce broad-spectrum immunity against multiple flaviviruses, enabling enhanced protection against emerging and re-emerging flaviviral threats.

The original patent disclosed a recombinant measles virus expressing Zika virus prM and E proteins, which, while effective, has limitations in terms of its narrow scope and potential for improved immunogenicity. The new inventive concept addresses these limitations by envisioning a more ambitious and forward-thinking approach, leveraging chimeric antigens and optimized expression systems to confer broader protection against flaviviruses.

The inventive concept comprises a system for inducing broad-spectrum immunity against flaviviruses, utilizing recombinant measles virus vectors expressing chimeric antigens comprising at least two distinct flaviviral envelope proteins. The chimeric antigens are optimized for enhanced immunogenicity and cross-reactivity, allowing for improved protection against multiple flaviviruses. The inventive concept also encompasses methods for generating flavivirus vaccines, comprising steps for selecting and designing chimeric antigens, and expressing them in recombinant measles virus vectors. Additionally, the inventive concept includes vaccine compositions comprising the recombinant measles virus vectors and pharmaceutically acceptable adjuvants, as well as methods for treating or preventing flavivirus infections using these compositions.

The new claims introduce the concept of chimeric antigens, optimized expression systems, and broad-spectrum immunity against flaviviruses, which are novel and non-obvious improvements over the original patent. The inventive concept's use of recombinant measles virus vectors to express chimeric antigens, and its focus on inducing broad-spectrum immunity, represent a significant departure from the original patent's narrow scope and approach.

Alternative embodiments of the inventive concept could include the use of different viral vectors, such as adenovirus or lentivirus, to express the chimeric antigens. Additionally, the inventive concept could be adapted for use in different animal models or human populations, or to target specific flaviviral strains or serotypes.

The inventive concept has significant commercial potential in the vaccine industry, particularly in the context of emerging and re-emerging flaviviral threats. The platform's ability to confer broad-spectrum immunity against multiple flaviviruses could make it an attractive solution for governments, public health organizations, and pharmaceutical companies seeking to develop effective countermeasures against these diseases. The target market could include countries with high flavivirus incidence, as well as global health organizations and NGOs focused on infectious disease prevention and control.